Pre-made Tabituximab benchmark antibody ( Whole mAb ADC, anti-FZD10 therapeutic antibody, Anti-CD350/FZ-10/Fz10/FzE7/hFz10 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tabituximab biosimilar, Whole mAb ADC, Anti-FZD10 Antibody: Anti-CD350/FZ-10/Fz10/FzE7/hFz10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-541-1mg	1mg	Inquiry
GMP-Bios-ab-541-10mg	10mg	Inquiry
GMP-Bios-ab-541-100mg	100mg	Inquiry
GMP-Bios-ab-541-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tabituximab biosimilar, Whole mAb ADC, Anti-FZD10 Antibody: Anti-CD350/FZ-10/Fz10/FzE7/hFz10 therapeutic antibody
INN Name	Tabituximab
Target	FZD10
Format	Whole mAb ADC
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	OncoTherapy Science;Centre Leon Berard
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Synovial sarcoma
Development Tech	na